KIMS Hospitals Revises Investor Call Date to Feb 9, 2026, Post Q3 FY26 Results
Krishna Institute of Medical Sciences Limited (KIMS) will host a revised investor conference call on February 9, 2026, at 9:30 a.m. IST. The call, organized by IIFL Capital, follows the declaration of the company's Q3 FY26 financial results. Management will discuss business strategy and outlook.
This is a rescheduling of an existing event, a conference call. It does not introduce new material information about the company's performance or strategic direction, thus having a minimal impact.
The announcement is a routine update regarding a rescheduled investor call and does not contain new financial performance data or strategic changes that would warrant a positive or negative sentiment.
Krishna Institute of Medical Sciences Limited (KIMS) has issued a revised intimation regarding a conference call for analysts and investors. The call, hosted by IIFL Capital, will now take place on Monday, February 9, 2026, at 9:30 a.m. IST. This call is scheduled to discuss the company's business strategy and outlook following the declaration of its Q3 FY26 financial results.
The initial intimation was dated February 2, 2026, and this revision adheres to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The revised copy of the invite for the conference call, as circulated by the host, has been enclosed.
Management participants in the call will include Dr. Bhaskara Rao Bollineni (Founder & Managing Director), Dr. Abhinay Bollineni (Executive Director & CEO), and Mr. Sachin Salvi (Chief Financial Officer). The call will also be accessible in Hong Kong/Singapore at 12:00 pm, UK at 4:00 am, and USA at 11:00 pm ET on the same day. Specific dial-in numbers for India and international callers are provided, along with contact details for further information.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.